Next generation antibody drugs: pursuit of the 'high-hanging fruit' von Carter, Paul J., Lazar, Greg A.

Volltext

Avidity in antibody effector functions and biotherapeutic drug design von Oostindie, Simone C., Lazar, Greg A., Schuurman, Janine, Parren, Paul W. H. I.

Volltext

Enhanced antibody half-life improves in vivo activity von Karki, Sher, Leung, Irene W L, Horton, Holly M, Chamberlain, Aaron K, Roopenian, Derry C, Desjarlais, John R, Lazar, Greg A, Zalevsky, Jonathan, Sproule, Thomas J

Volltext

Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets von Romei, Matthew G., Leonard, Brandon, Kim, Ingrid, Kim, Hok Seon, Lazar, Greg A.

Volltext

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions von Moore, Gregory L., Chen, Hsing, Karki, Sher, Lazar, Greg A.

Volltext

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists von Romei, Matthew G., Leonard, Brandon, Katz, Zachary B., Le, Daniel, Yang, Yanli, Day, Eric S., Koo, Christopher W., Sharma, Preeti, Bevers III, Jack, Kim, Ingrid, Dai, Huiguang, Farahi, Farzam, Lin, May, Shaw, Andrey S., Nakamura, Gerald, Sockolosky, Jonathan T., Lazar, Greg A.

Volltext

Engineered Antibody Fc Variants with Enhanced Effector Function von Lazar, Greg A., Dang, Wei, Karki, Sher, Vafa, Omid, Peng, Judy S., Hyun, Linus, Chan, Cheryl, Chung, Helen S., Eivazi, Araz, Yoder, Sean C., Vielmetter, Jost, Carmichael, David F., Hayes, Robert J., Dahiyat, Bassil I.

Volltext

Novel Interface for High-Throughput Analysis of Biotherapeutics by Electrospray Mass Spectrometry von Park, Hae-Min, Winton, Valerie J, Drader, Jared J, Manalili Wheeler, Sheri, Lazar, Greg A, Kelleher, Neil L, Liu, Yichin, Tran, John C, Compton, Philip D

Volltext

Antibody homotypic interactions are encoded by germline light chain complementarity determining region 2 von Leonard, Brandon, Sankar, Kannan, Romei, Matthew G, Tse, Margaret J, Do, Nina, Yang, Yanli, Matochko, Wadim L, Bevers, Jack, Bollineni, Sundeep, Mukhyala, Kiran, Hoi, Kam Hon, Lazar, Greg A

Volltext

Characterizing and Quantitating Therapeutic Tethered Multimeric Antibody Degradation Using Affinity Capture Mass Spectrometry von Li, Wenjing, Srikumar, Neha, Forrest, William F, Ellerman, Diego, Gu, Chen, Tchelepi, Robert, Lazar, Greg A, Liu, Yichin, Tran, John C

Volltext

Modulation of antibody effector function von Desjarlais, John R., Lazar, Greg A.

Volltext

An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans von Chung, Shan, Nguyen, Van, Lin, Yuwen Linda, Lafrance-Vanasse, Julien, Scales, Suzie J, Lin, Kevin, Deng, Rong, Williams, Kathi, Sperinde, Gizette, Li, Juan Jenny, Zheng, Kai, Sukumaran, Siddharth, Tesar, Devin, Ernst, James A, Fischer, Saloumeh, Lazar, Greg A, Prabhu, Saileta, Song, An

Volltext

Attachment Site Cysteine Thiol pK a Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody–Drug Conjugates von Vollmar, Breanna S, Wei, Binqing, Ohri, Rachana, Zhou, Jianhui, He, Jintang, Yu, Shang-Fan, Leipold, Douglas, Cosino, Ely, Yee, Sharon, Fourie-O’Donohue, Aimee, Li, Guangmin, Phillips, Gail L, Kozak, Katherine R, Kamath, Amrita, Xu, Keyang, Lee, Genee, Lazar, Greg A, Erickson, Hans K

Volltext

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates von Vollmar, Breanna S, Wei, Binqing, Ohri, Rachana, Zhou, Jianhui, He, Jintang, Yu, Shang-Fan, Leipold, Douglas, Cosino, Ely, Yee, Sharon, Fourie-O’Donohue, Aimee, Li, Guangmin, Phillips, Gail L, Kozak, Katherine R, Kamath, Amrita, Xu, Keyang, Lee, Genee, Lazar, Greg A, Erickson, Hans K

Volltext

Susceptibility of Antibody CDR Residues to Chemical Modifications Can Be Revealed Prior to Antibody Humanization and Aid in the Lead Selection Process von Xu, Ankai, Kim, Hok Seon, Estee, Samarkand, ViaJar, Sharon, Galush, William J, Gill, Avinash, Hötzel, Isidro, Lazar, Greg A, McDonald, Paul, Andersen, Nisana, Spiess, Christoph

Volltext

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective von Desjarlais, John R., Lazar, Greg A., Zhukovsky, Eugene A., Chu, Seung Y.

Volltext

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens von Moore, Gregory L., Bautista, Cristina, Pong, Erik, Nguyen, Duc-Hanh T., Jacinto, Jonathan, Eivazi, Araz, Muchhal, Umesh S., Karki, Sher, Chu, Seung Y., Lazar, Greg A.

Volltext

Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members von Yang, Yanli, Yeh, Sherry H, Madireddi, Shravan, Matochko, Wadim L, Gu, Chen, Pacheco Sanchez, Patricia, Ultsch, Mark, De Leon Boenig, Gladys, Harris, Seth F, Leonard, Brandon, Scales, Suzie J, Zhu, Jing W, Christensen, Erin, Hang, Julie Q, Brezski, Randall J, Marsters, Scot, Ashkenazi, Avi, Sukumaran, Siddharth, Chiu, Henry, Cubas, Rafael, Kim, Jeong M, Lazar, Greg A

Volltext

Fc‐engineered EGF‐R antibodies mediate improved antibody‐dependent cellular cytotoxicity (ADCC) against KRAS‐mutated tumor cells von Schlaeth, Martin, Berger, Sven, Derer, Stefanie, Klausz, Katja, Lohse, Stefan, Dechant, Michael, Lazar, Greg A., Schneider‐Merck, Tanja, Peipp, Matthias, Valerius, Thomas

Volltext

High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants von DiCara, Danielle M, Andersen, Nisana, Chan, Ruby, Ernst, James A, Ayalon, Gai, Lazar, Greg A, Agard, Nicholas J, Hilderbrand, Amy, Hötzel, Isidro

Volltext